CDNA - CareDx, Inc. Latest News | Finranks

CDNA - CareDx, Inc. Latest News | Finranks

CareDx Introduces VANTx AI Platform for Complex Transplant Datasets

CareDx Introduces VANTx AI Platform for Complex Transplant Datasets

CDNA launches VANTx, an AI-driven cloud platform that turns complex transplant datasets into insights to support clinical research and real-world evidence.

CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx's Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets

CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx's Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the launch of VANTx™, an AI‑powered, cloud‑native clinical data and analytics platform designed to transform complex transplant data into insights that support clinical research and real‑world.

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On February 24, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an agg.

CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript

CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript

CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript

CareDx (CDNA) Reports Q4 Earnings: What Key Metrics Have to Say

CareDx (CDNA) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

CareDx (CDNA) Q4 Earnings Miss Estimates

CareDx (CDNA) Q4 Earnings Miss Estimates

CareDx (CDNA) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.18 per share a year ago.

CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company's Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company's finance organization effective.

Videos

No Data

There is no data to display